Homepage
Author:
Structure Therapeutics Inc.
Posted Date:
April 27, 2026
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
Structure Therapeutics Inc.
April 27, 2026
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
Structure Therapeutics Inc.
April 14, 2026
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Structure Therapeutics Inc.
March 16, 2026
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Structure Therapeutics Inc.
February 27, 2026
